TECX Tectonic Therapeutic, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1681087 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-30.9%
TTM EPS YoY-72.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-35.5%
ROA-33.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6.0%
Debt / equity0.00x
Current ratio19.71x
Interest coverage-3,216.43x
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $63.49M | $41.36M | $36.97M | $72.19M | $83.11M |
| SG&A expense | $20.55M | $16.65M | $7.68M | $33.25M | $35.73M |
| Operating income | -$84.04M | -$58.02M | -$44.65M | -$105.43M | -$118.84M |
| Interest expense | $63,000 | $107,000 | $152,000 | $1.81M | $203,000 |
| Pretax income | -$72.92M | -$57.98M | — | — | — |
| Income tax | $1.23M | $0 | $0 | $0 | — |
| Net income | -$74.15M | -$57.98M | -$42.82M | -$105.89M | -$119.13M |
| EBITDA | -$82.66M | -$56.37M | -$43.17M | -$103.99M | -$117.44M |
| EPS (basic) | -4.05 | -6.83 | -33.76 | -2.42 | -2.78 |
| EPS (diluted) | -4.05 | -6.83 | -33.76 | -2.42 | -2.78 |
| Dividends declared per share | 0.00 | 0.00 | — | — | — |
| Weighted avg. shares (diluted) | 18.32M | 8.49M | 1.27M | 43.74M | 42,854 |
| Balance sheet | |||||
| Cash & equivalents | $253.80M | $141.83M | $29.36M | $36.55M | $190.06M |
| Current assets | $257.36M | $146.86M | $30.88M | $99.96M | $199.15M |
| PP&E, net | $1.19M | $2.15M | $3.12M | $2.89M | $4.13M |
| Total assets | $261.04M | $152.91M | $39.40M | $103.95M | $203.84M |
| Current liabilities | $9.67M | $11.61M | $40.89M | $13.12M | $19.39M |
| Long-term debt | — | — | — | $15.00M | $15.00M |
| Total debt | — | — | — | $15.00M | $15.00M |
| Total liabilities | $9.71M | $12.13M | $43.41M | $28.58M | $34.36M |
| Shareholders' equity | $251.33M | $140.78M | -$84.64M | -$45.65M | $169.48M |
| Net debt | — | — | — | -$21.55M | -$175.06M |
| Shares outstanding | 18.74M | 14.86M | 1.41M | 43.92M | 43.65M |
| Cash flow statement | |||||
| Operating cash flow | -$60.08M | -$59.08M | -$40.68M | -$97.21M | -$98.03M |
| Capital expenditure | $208,000 | $156,000 | $279,000 | $267,000 | $2.46M |
| Free cash flow | -$60.29M | -$59.24M | -$40.96M | -$97.47M | -$100.49M |
| Investing cash flow | -$138,000 | -$156,000 | -$279,000 | -$267,000 | -$2.46M |
| Financing cash flow | $173.35M | $171.71M | $33.75M | $262,000 | $30.37M |
| Depreciation & amortization | $1.38M | $1.65M | $1.48M | $1.44M | $1.40M |
| Stock-based compensation | $10.50M | $3.49M | $1.12M | $11.52M | $18.58M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.